Multi-Omics in Childhood Cancer
This lab is researching how we could improve diagnosis, prognosis and treatment decisions in the future with different types of molecular data from a child’s cancer.
A cancer’s molecular makeup can tell us a lot about what kind of cancer it is, and how best it can be treated. The Multi-Omics in Childhood Cancer research lab, led by Dr Rebecca Poulos, is working out new ways to use the molecular profile of an individual’s cancer to identify signatures that can predict outcome and treatment response for that child. By working closely with oncologists, and focusing particularly on proteomics, research findings are aiming for rapid future translation to the clinic.
This research focuses on identifying molecular signatures that can predict important outcomes in hard-to-treat paediatric cancers, such as relapse, metastasis and overall survival. The ultimate goal is to use these signatures to improve prognosis and tailor treatments for better efficacy by developing more targeted therapies that address the unique challenges of these cancers.
By seeking to integrate mass spectrometry-based proteomics into current precision medicine initiatives, this theme seeks to enhance the accuracy of disease characterisation and treatment personalisation by examining the protein content of an individual’s cancer. This approach allows for a deeper understanding of the proteomic landscape, leading to more precise and effective interventions that target a patient’s protein profile.
This theme explores the relationship between genomic and transcriptomic features at the protein level, providing insights into how genetic information translates into functional proteins and impacts disease mechanisms. By bridging these molecular layers, we can uncover novel biomarkers and therapeutic targets and identify which data layers can most accurately distinguish certain molecular features.
RC Poulos*, PG Hains* and R Shah* [* joint first authors], N Lucas, D Xavier, S Manda, A Anees, JMS Koh, S Mahboob, M Wittman, SG Williams, EK Sykes, M Hecker, M Dausmann, MA Wouters, K Ashman, J Yang, P Wild, A deFazio, R Balleine, B Tully, Y Liu, R Aebersold, T Speed, RR Reddel, PJ Robinson, Q Zhong, Strategies to enable large-scale proteomics for reproducible research, Nature Communications*, 2020; 11(1).
E Goncalves*, RC Poulos*, Z Cai*# [* joint first authors], S Barthorpe, SS Manda, N Lucas, A Beck, D Bucio-Noble, M Dausmann, C Hall, M Hecker, J Koh, H Lightfoot, S Mahboob, I Mali, J Morris, L Richardson, AJ Seneviratne, R Shepherd, E Sykes, F Thomas, S Valentini, SG Williams, Y Wu, D Xavier, KL MacKenzie, PG Hains, B Tully, PJ Robinson, Q Zhong, MJ Garnett & RR Reddel, Pan-cancer cell line proteomic map, Cancer Cell, 2022; 40(8).
RC Poulos, Z Cai, PJ Robinson, RR Reddel, Q Zhong, Opportunities for pharmacoproteomics in biomarker discovery, Proteomics, 2022, 23(7-8).
BD Padhye, Q Zhong, PJ Robinson, RR Reddel, RC Poulos, Proteomic Insights into Paediatric Cancer: Unravelling Molecular Signatures and Therapeutic Opportunities, Pediatric Blood & Cancer, 2024, 71(6).